# Dihydropyridine derivatives and their production, formulation and use as pharmaceuticals.

## Abstract
There are described compounds of formula I, CHEM in which R2 and R3, which may be the same or different, each represent alkyl C1 to 6 or cycloalkyl C3 to 8, R7 and R8, which may be the same or different, each represent alkyl C1 to 6 optionally substituted by halogen, and X, Y and Z, which may be the same or different, are each hydrogen, halogen, nitro or alkyl C1 to 6 optionally substituted by halogen, or Z is as defined above and X and Y, together with the carbon atoms to which they are attached, form a C5 to 8 carbocyclic ring, other than a benzene ring, provided that when R2, R3, R7 and R8 are all methyl and X and Z are hydrogen or when R2 and R3 are both ethyl, R7 and R8 are both ethyl and X and Z are hydrogen then Y is other than methyl. There are also described methods for making the compounds and their formulation and use as pharmaceuticals, e.g. for the treatment of cardiovascular conditions.

## Claims
What we claim is EMI23.1 in which R2 and R3, which may be the same or different, each represent alkyl C1 to. 6 or cycloalkyl C3 to .8, pR7 and R8, which may be the same or different, each represent alkyl C1 to 6 optionally substituted by halogen, and X, Y and Z, which may be the same or different, are each hydrogen, halogen , nitro or alkyl Cm to 6 optionally substituted by halogen, or 2 is as defined above and X andY, together with the carbon atoms to which they are attached, form a C5 to 8 carbocyclic ring, other than a benzene ring, provided that when R2, R3, R7 and R8 are all methyl and X and Z are hydrogen or when R2 and R3 are both ethyl, R7 and R8 are both methyl and X and Z are hydrogen then Y is other than methyl. 2. A compound according to claim 1, wherein R2 andR3 are selected from methyl and l methylethyl. 3. A compound according to claim 1 or 2, wherein R7 and R8 are selected from methyl and monofluoromethyl. 4. A compound according to any one of the preceding claims, wherein Z is chloro, bromo, methyl or CF3, Y is hydrogen or chloro, and X is hydrogen or chloro, or Y andZ together form a CH2 3 or CH2 4 chain. 5. A compound according to any one of claims 1 to 4, wherein X and Y, together with the carbon atoms to which they are attached, form a ring of formula,EMI24.1 in which Z is as defined in claim 1, and A is CH2 or CH2CH2 . 6. 3 Methyl 5 1 methylethyl 4 2 chloro 1 cyclohexenyl 2 fluoromethyl 1,4 dihydro 6 methyl 3, 5 pyridinedicarboxylate, 3 Methyl 5 1 methylethyl 4 2 chloro 1 cyclopentenyl 2 fluoromethyl 1,4 dihydro 6 methyl 3, 5 pyridinedicarboxylate, 3 Methyl 5 l methylethyl 4 2 chloro 1 cyclohexenyl 1,4 dihydro 2,6 dimethyl 3, 5 pyridinedicarboxylate, 3 Methyl 5 1 methylethyl 2 fluoromethyl l,4 dihydro 6 methyl 4 2 methyl 1 cyclohexenyl 3,5 pyridinedicarboxylate, 3 Methyl 5 1 methylethyl 4 2,2 dichloroethenyl 2 fluoromethyl 1,4 dihydro 6 methyl 3,5 pyridinedicarboxy late, bis l methylethyl 4 2,2 dichloroethenyl 1,4 dihydro 2,6 dimethyl 3,5 pyridinedicarboxylate, 3 Methyl 5 1 methylethyl 2 fluoromethyl 1,4 dihydro 6 methyl 4 1,2,2 trichloroethenyl 3,5 pyridinedicarboxylate, 3 Methyl 5 l methylethyl 4 bicyclo 2.2.2 oct 2 en 2 yl 2 fluoromethyl 1,4 dihydro 6 methyl 3,5 pyridine dicarboxylate, 3 Methyl 5 1 methyl ethyl 4 3 chlorobicyclo 2.2.2 oct 2 en 2 yl 2 fluoromethyl 1,4 dihydro 6 methyl 3,5 pyridinedicarboxylate, 3 Methyl 5 1 methyl ethyl 4 2 bromo l cyclohexenyl 2 fluoromethyl 1,4 dihydro 6 methyl 3,5 pyridine dicarboxylate, or 3 Methyl 5 1 methylethyl 2 fluoromethyl l, 4 dihydro 6 methyl 4 2 trifluoromethyl l cyclohexenyl 3,5 pyridinedicarboxylate. 7. A pharmaceutidal formulation comprising a compound according to any one of the preceding claims in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. 8. The use of a compound according to any one of claims 1 to 6 as a pharmaceutical. 9. The use of a compound according to any one of claims 1 to 6 to make a pharmaceutical formulation for use in the treatment of a cardiovascular condition. 10. A process for the production of a compound of formulaI, as defined in claim 1, which comprises a reaction of a compound of formula II, YZC CXCHO II either with a compound of formula III or with compounds of formulae III and IV, R200CCH C R7 NE2 III R30OCCH2COR8 IV in which formulae Y,Z,X, R2, R3, R7 and R8 are as defined.in claim 1, b reaction of a compound of formula V, YZC CX CH C COOR3 COR8 V in which Y, Z X, R3 and R8 are as defined in claim 1, with a compound of formula III., or c production of an optical isomer of a compound of formula I by resolution of a mixture of optical isomers of the compound. 1383J ir jaa What we claim is 1. A process for the production of a compound of formula I,EMI27.1 in which R2 and R3, which may be the same or different, each represent alkyl C1 to 6 or cycloalkyl C3 to 8, R7 and R8, which may be the same or different, each represent alkyl C1 to 6 optionally substituted by halogen, and X, Y and Z, which may be the same or different, are each hydrogen, halogen, nitro or alkyl Cl to 6 optionally substituted by halogen, or Z is as defined above and X andY, together with the carbon atoms to which they are attached, form a C5 to 8 carbocyclic ring, other than a benzene ring, provided that when R2, R3, R7 and R8 are all methyl and X and Z are hydrogen or when R2 and R3 are both ethyl, R7 and R8 are both methyl and X and Z are hydrogen then Y is other than methyl, which comprises a reaction of a compound of formula II, YZC CXCHO II either with a compound of formula III or with compounds of formulae III and IV, R200CCH C R7 NH2 III R300CCH2COR8 IV in which formulae Y,Z,X, R2, R3, R7 and R8 are as defined in claim 1, b reaction of a compound of formula V, YZC CX CH C COOR3 COR8 V in which Y, Z, X, R3 and R8 are as defined in claim 1, with a compound of formula III, or c production of an optical isomer of a compound of formula I by resolution of a mixture of optical isomers of the compound. 2. A process according to claim 1, wherein R2 and R3 are selected from methyl and 1 methylethyl. 3. A process according to claim 1 or 2, wherein R7 andR8 are selected from methyl and monofluoromethyl. 4. A process according to any one of the preceding claims, wherein Z is chloro, bromo, methyl or CF3, Y is hydrogen or chloro, and X is hydrogen or chloro, or Y andZ together form a CH2 3 or CH2 4 chain. 5. A process according to any one of claims 1 to 4, wherein X and y, together with the carbon atoms to which they are attached, form a ring of formula,EMI29.1 in which Z is as defined in claim 1, and A is CH2 or CH2CH2 . 6. A process according to any one of the preceding claims, whereing the compound of formula I is 3 Methyl 5 1 methylethyl 4 2 chloro 1 cyclohexenyl 2 fluoromethyl 1,4 dihydro 6 methyl 3, 5 pyridinedicarboxylate. 7. A process according to any one of claims 1 to 5, wherein the compound of formula I is 3 Methyl 5 1 methylethyl 4 2 chloro 1cyclopentenyl 2 fluoromethyl 1,4 dihydro 6 methyl 3, 5 pyridinedicarboxylate, 3 Methyl 5 1 methylethyl 4 2 chloro 1 cyclohexenyl l,4 dihydro 2, 6 dimethyl 3, 5 pyridinedicarboxylate, 3 Methyl 5 1 methylethyl 2 fluoromethyl l, 4 dihydro 6 methyl 4 2 methyl 1 cyclohexenyl 3,5 pyridinedicarboxylate, 3 Methyl 5 l methylethyl 4 2,2 dichloroethenyl 2 fluoromethyl l,4 dihydro 6 methyl 3,5 pyridinedicarboxy late, bis l methylethyl 4 2,2 dichloroethenyl l,4 dihydro 2,6 dimethyl 315 pyridinedicarboxylate, 3 Methyl 5 1 methylethyl 2 fluoromethyl l,4 dihydro 6 methyl 4 l,2,2 trichloroethenyl 3,5 pyridinedicarboxylate, 3 Methyl 5 1 methylethyl 4 bicyclo 2.2.21oct 2 en 2 yl 2 fluoromethyl 1,4 dihydro 6 methyl 3,5 pyridine dicarboxylate, 3 Methyl 5 1 methylethyl 4 3 chlorobicyclo 2.2.2 oct 2 en 2 yl 2 fluoromethyl 1,4 dihydro 6 methyl 3,5 pyridinedicarboxylate, 3 Methyl 5 1 methylethyl 4 2 bromo l cyclohexenyl 2 fluoromethyl l,4 dihydro 6 methyl 3,5 pyridine dicarboxylate, or 3 Methyl 5 1 methylethyl 2 fluoromethyl l, 4 dihydro 6 methyl 4 2 trifluoromethyl 1 cyclohexenyl 3,5 pyridinedicarboxylate. 8. The use of a compound according to any one of claims 1 to 7 to make a pharmaceutical formulation for use in the treatment of a cardiovascular condition.

## Description
DIHYDROPYRIDINE DEXARTrES AND THEIR PRODUCTION, FORMULATIONAND USE AS PHARMATEUTICALS This invention relates to new compounds, methods for their preparation and compositions containing them. A wide variety of dihydropyridines, e.g. those described in US Patent No 3,325,505, have been described as being useful as pharmaceuticals and some, notably nifedipine, have been sold for this use. We have now found a new group of pyridine derivatives which have pharmacological activity. According to the invention we provide compounds of formula I,EMI1.1 in which R2 and R3, which may be the same or different, each represent alkyl C1 to 6 or cycloalkyl C3 to 8, R7 and R8, which may be the same or different, each represent alkyl C1 to 6 optionally substituted by halogen, and X, Y and Z, which may be the same or different, are each hydrogen, halogen, nitro or alkyl C1 to 6 optionally substituted by halogen, or Z is as defined above and X and Y, together with the carbon atoms to which they are attached, form a C5 to 8 carbocyclic ring, other than a benzene ring, provided that when R2, R3, R7 and R8 are all methyl and X and S are.hydrogen or when R2 and R3 are both ethyl, R7 and R8 are both methyl and X and Z are hydrogen then Y is other than methyl. According to the invention we also provide the compounds of formula I for use as pharmaceuticals. According to the invention we further provide a process for the production of a compound of formula I which comprises a reaction of a compound of formula II, YZ C CXCHO II either with a compound of formula III or with compounds of formulae III and IV, R200CCH C R7 NE2 III 300CCH2COR8 IV in which formulae Y,Z,X, R2, R3, R7 and R8 are as defined above, b reaction of a compound of formula V, YZC CX CH C COOR3 COR8 in which Y, Z, X, R3 and R8 are as defined above, with a compound of formula III, or c production of an optical isomer of a compound of formula I by resolution of a mixture of optical isomers of the compound. The reaction of process a may be carried out by subjecting the compounds of formulae II, III and IV to an elevated temperature, eg of from about 200 and 1400C in the presence or absence of a suitable solvent, eg a lower alkanol or dimethylformamide. Alternatively the compound of formula II may be reacted with two moles of the compound of formula III to produce a symmetrical compound. Processes b may be carried out under similar conditions to process a . Process c may be carried out using conventional processes known per se. The starting materials for the above processes are either known, or if they are not specifically known they may be made by processes described in the Examples, or they may be made from known compounds using one or more process steps which are known per se or are analogous to those described in the Examples. The compounds of formula I and the intermediates therefor may be isolated from their reaction mixtures using conventional processes, eg crystallisation or chromatography. The compounds of formula I, are useful because they exhibit pharmacological properties in animals. More particularly they block the entry of calcium into vascular and cardiac muscle leading to falls in blood pressure, inotropy and heart rate. They. are active in the following systems a Relaxation of contracted vascular smooth muscle. Van Breeman, Aaronson, Loutzenhiser and Meisheri,Chest, 78, Supplement, 157 165, 1980. b Reduction of inotropy and chronotropy of isolated atria. Henry, .Excerpta Med. Int. Congr. Ser., 474, 14 23, 1979. c Reduction of blood pressure and increase cardiac output in anaesthetised dogs. Hirakawa, Ito,Kondo, Watanbe, Hiei, Banno Hyase, Arzneim Forsch, 22, 344 349, 1972. d Reduction of blood pressure in conscious dogs when given by the intravenous and oral routes. Newman,Bishop, Peterson, Leroux Horowitz, J Pharm. Exp. Ther.201, 723 730, 1977. The compounds are thus indicated for use in the treatment of renovascular, malignant or essential hypertension including hypertensive emergencies , pulmonary hypertension, vasospastic angina, chronic stable angina and congestive heart failure. Other indications are the treatment of renal failure, cardiac arrhythmias, hypertrophic cardiomyopathy, cerebrovascular diseases including cerebral haemorrhage, ischaemia and vasospasm, migraine, altitude sickness and hearing loss , peripheral vascular diseases including Raynaud s syndrome, intermittent claudication and digital ulceration use as a cardioplegic agent during surgery, e.g. in cardiopulmonary bypass, and for the treatment of, and protection against, myocardial infarction and ischaemia. By virtue of their ability to inhibit calcium entry into other cells and tissues the compounds are also indicated in the treatment of thrombosis, atherosclerosis, respiratory diseases including asthma and bronchitis glaucoma, aldosteronism, uterine hypermotility and for the relief of oesophageal and skeletal muscle spasm. For the above uses the dosage will depend upon the compound used, the route of administration and the effect desired, but in general will be in the range of O.l lOmg per kilogram body weight per day. For man the indicated total daily dose will be from about 5 500mg, preferably from 5 to 200mg and more preferably from 5 to 100mg, which may be administered preferably once daily, or in divided doses of about 1 200mg, preferably 2 to 25mg, e.g. 2 to 4 times per day. The compounds of formula I are advantageous in that they possess greater potency e.g. with respect to hypotensive and direct negative chronotropic effects , produce a lower level of reflex tachycardia, are more selective e.g. for vascular smooth muscle vs cardiac muscle , produce less depression of cardiac contractility, are longer acting, are more readily absorbed or less readily metabolised, are more easily formulated, possess less, or less undesirable, side effects, are more stable or have other more beneficial properties than known compounds of similar structure. The compounds of the invention may be administered by a wide variety of routes and may act systemically or locally. Thus the compounds may be administered by oral or nasal inhalation to the lung, to the buccal cavity, oesophageally, rectally, topically to the skin, the eye or to other available surfaces of the body by injection, e.g. intravenously, intramuscularly, intraperitoneally, or by surgical implant. We prefer R2 and R3 to be selected from methyl, ethyl, l methylethyl, cyclobutyl and cyclopentyl. We particularly prefer R2 to be l methylethyl, cyclobutyl or cyclopentyl and R3 to be methyl. We prefer R7 andR8 to be selected from methyl and monofluoromethyl, and especially for R7 to be methyl and R8 to be monofluoromethyl. Z may be fluoro, chloro, bromo, CF3, NO2 or methyl X may be fluoro, chloro, methyl or hydrogen Y may be CF3, fluoro, chloro, methyl, NO2 or hydrogen or X and Y may together form a CH2 n chain in which n is 3 or 4. When X and Y, together with the carbon atoms to which they are attached, form a cartocyclic ring that ring may be a bridged ring, e.g. a ring of formula,EMI7.1 in which Z is as defined above, and A is CH2 or CH2CH2 According to our invention we also provide a pharmaceutical composition comprising preferably less than 80 , more preferably less than 50 , e.g. 1 to 20 , by weight of a compound of formula I, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Thus the compound may be put up as a tablet, capsule, dragee, suppository, suspension, solution, injection, implant, a topical, e.g. transdermal, preparation such as a gel, cream, ointment, aerosol or a polymer system, or an inhalation form, e.g. an aerosol or a powder formulation. We prefer compositions which are designed to be taken oesophageally and to release their contents in the gastrointestinal tract. Thus we prefer tablets which may, for example, be made by direct compression. In such a process the active ingredient is mixed with one or more of modified forms of starch, calcium phosphate, a sugar, e.g . lactose, microcrystalline cellulose and or other directly compressible exc ipients, together with lubricant s , e.g. stearic acid or magnesium stearate, flow aid s , e.g. talc or colloidal silicon dioxide, and disintegrant s , e.g. starch, substituted sodium carboxymethyl cellulose, cross linked.sodium carboxy methyl cellulose, carboxy methyl starch and cross linked polyvinylpyrrolidone. Tablets are then formed by direct compression, and may be sugar or film coated, e.g. with hydroxpropylmetbylcellulos e. Alternatively the active ingredient may be granulated before tabletting. In such cases the active ingredient is mixed with one or more of starch, calcium phosphate, a sugar, e.g. lactose, microcrystalline cellulose or other suitable excipients and granulated with a binder such as starch, pregelled starch, polyvinylpyrrolidone, gelatine, a modified gelatine, or a cellulose derivative, e.g.hydroxypropylmethylcellulose. The mass is then dried, sieved and mixed with lubricant s , flow aid s and disintegrant s , such as described in the previous paragraph. Tablets are then formed by compression of the granules, and may be sugar or film coated, e.g. with hydroxypropylmethylcellulose. As a further alternative a powder, blend or granules, such as are described above as intermediates in tab letting, may be filled into a suitable, e.g. gelatine, capsule. In order to improve the bioavailability, or decrease variability of availability, of the active ingredient the compound may be a dissolved in a suitable solvent, e.g. polyethylene glycol, Gelucaire, arachis oil, a hydrogenated vegetable oil or beeswax and the solution is then filled into a gelatine capsule, b produced as a spray dried or freeze dried form prior to mixing with other excipients, c milled and or micronised to produce a powder with a large surface area prior to mixing with other excipients, d made into a solution and distributed over an inert excipient having a large surface area, e.g. colloidal silicon dioxide. The solvent is evaporated and further excipients added, e formed into a complex with cyclodextrin prior to mixing with other excipients. This complex also assists in increasing light stability, or f made into a solid solution or co precipitated, e.g. with polyvinylpyrrolidone, polyethyleneglycol, modified cellulose, hydroxypropylmethylcellulose, urea or a sugar prior to mixing with further excipients. The compounds, either in their normal form or in a modified form, e.g as described immediately above, may be formulated in a controlled release form. Thus the compound may be dispersed, or contained in, a polymer matrix formed from, for example, ethylcellulose, hydroxypropylmethylcellulose or an acrylate methacrylate polymer. Alternatively the compound may be formulated as a tablet or beads which are surrounded by a semi permeable membrane, e.g. shellac, ethylcellulose or an acrylate methacrylate polymer. The compounds of this invention may be given in combination with other pharmaceutically active compounds, e.g. diuretics, beta blockers, antihypertensives 6r inotropic agents. The dosage of the other pharmaceutically active compound can be that conventionally used when the compound is administered on its own, but is preferably somewhat lower.To illustrate these combinations, a compound of this invention effective in the range, e.g. 5 100 milligrams per day, can be combined at levels ranging. e.g. from 1 200 milligrams per day with the following beta blockers, antihypertensives and diuretics in dose ranges per day as indicated hydrochlorothiazide 15 200mg , chlorothiazide l25 2000mg , ethacrynic acid 15 lOOmg , amiloride 5 20mg , furosemide 5 80mg , propanolol 20 480mg , timolol 5 50mg , captopril 10 500mg , methyldopa 65 2000mg or digoxin 0,1 015mg . In addition, the triple drug combinations of hydrochlorothiazide 15 200mg plus amiloride 5 20mg plus a compound of this invention 3 200m and hydrochlorothiazide 15 200mg plus timolol 5 200mg plus a compound of this invention 3 200mg , are provided. The above dose ranges may be adjusted on a unit basis as necessary to permit divided daily dosage.Also, the dose may vary depending on the severity of the disease, weight of patient and other factors which a person skilled in the art will recognise. Certain of the compounds of formula I are assymetric and exhibit optical isomerism. Such compounds may be separated into their optical isomers using process c or.may be made by stereospecific syntheses using conventional techniques known per se. The invention therefore provides the compounds as their individual optical isomers, and racemic or other mixtures of the individual isomers. Certain of the compounds of the invention can form solvates, e.g. hydrates or alcoholates, and certain of the compounds are light sensitive and should therefore be produced, handled, stored and formulated in such a manner that they are not subjected to degrading amounts of light of the appropriate wavelengths. The invention is illustrated, but in no way limited by the following Examples in which temperatures are in degrees centigrade.Example 1 3 Methyl 5 1 methylethyl 4 2 chloro 1 cyclohexenyl 2 fluoromethyl 1,4 dihydro 6 methy1 3, 5 pyr idinedicarboxylate 2 Chlor o l cycloh exe ne l car boxalde hyde 2 . 9g, 20 mmoles , methyl 4 fluoro 3 oxobutanoate 2.7g, 20 mmoles and l methylethyl 3 amino 2 butenoate 2.88g, 20 mmoles in dried tert butanol 40ml was heated with stirring under nitrogen at 350 for 96 hours. The solvent was removed in vacuo and the resulting red oil was purified byHPLC using 20 ethyl acetate in petroleum ether 60 800 as eluant.Pure fractions were combined and evaporated to dryness and the title compound 0.48g obtained by crystallization from hexane. mp 118 90. Example 2 3 Methyl 5 1 methylethyl 4 2 chloro l cyclopentenyl 2 fluoromethyl 1,4 dihydro 6 methyl 3, 5 pyridinedicarboxylate 2 Chloro l cyclopentene l carboxaldehyde 3. lug, 23.7 mmoles , methyl 4 fluoro 3 oxobutanoate 3.18g, 23.7 mmoles and l methylethyl 3 amino 2 butenoate 3.4g, 23.7 mmoles in dried tert butanol 40ml was heated with stirring under nitrogen at 45 for 15 hours. The solvent was removed in vacuo and the resulting red oil was purified by HPLC using 20 ethyl acetate in petroleum ether 60 80 as eluant.Pure fractions were combined and evaporated to dryness and the title compound 2.75g obtained by crystallization from cyclohexane. mp 133 35 . Example 3 3 Methyl 5 1 methylethyl 4 2 chloro 1 cyclohexenyl 1, 4 dihydro 2 , 6 dimethyl 3 5 pyridinedicarboxylate 2 Chloro l cyclohexene l carboxaldehyde 5.76g, 40 mmoles , methyl 3 oxobutanoate 4.649, 40 mmoles and l methylethyl 3 amino 2 butenoate 5.72g, 40 mmoles were heated with stirring at 950 for 2.5 hours. The reaction mixture was dissolved in ethyl acetate and chromatographed by preparative HPLC eluting with petroleum ether 60 80 0 ethyl acetate mixtures. Pure fractions were combined and evaporated to dryness. The title compound 0.199 was obtained by crystallization from cyclohexane.mp 133 4 . Example 4 3 Methyl 5 1 methylethyl 2 fluoromethyl 1,4 dihydro 6 metyl 4 2 methyl l cyclohexe pyridinedicarboxylate 2 Methyl 1 cyclohexene 1 carboxaldehyde 0.7g, 5.6mmoles , methyl 4 fiuoro 3 oxobutanoate 0.76g, 5.6mmoles and l methylethyl 3 amino 2 butenoate 0.81g, 5.6mmoles were heated with stirring under N2 at 600 for 16 hours. The reaction mixture was cooled and then chromatographed on silica eluting with ethyl acetate petroleum ether 60 80 mixtures. Pure fractions were combined and evaporated and the title compound 0.13g was obtained by crystallisation from petroleum ether 60 80 mp 136 7 . Example 5 3 Methyl 5 1 methylethyl 4 2, 2 dichioroethenyl 2 fluoromethy 4 dihydro 6 methyl 3,5 pyridinedicarboxy late and bis l methylethyl 4 2,2 dichloroethenyl 1,4 dihydro 2,6 dimethyl 3,5 pyridinedicarboxylate l Methylethyl 3 amino 2 butenoate 1. Ig, 8mmoles was added to a stirred mixture of 3,3 dichloropropenal 1.0g, 8mmoles and methyl 4 fluoro 3 oxobutanoate l.lg, Smmoles . After 1 hour at room temperature and 2 hours at 950, the reaction mixture was cooled and then purified by chromatography on silica eluting with ethyl acetate petroleum ether 60 80 mixtures.The first eluted product was the 2 fluoromethyl 6 methyldihydropyridine which was crystallised from petroleum ether 60 80 to give a white solid 0.35g mp 19 200. The second eluted product was the 2,6 dimethyldihydropyridine which was crystallised from petroleum ether 60 80 give a white solid 0.32g uu I mp 123 4 Example 6 3 Methyl 5 1 methylethyl 2 fluoromethyl 1,4 dihydro 6 methyl 4 1,2, 2 trichioroethenyl 3,5 pyridinedicarboxylate 2,3,3 Trichloropropenal 0.62g, 3.8mmoles , methyl 4 fluoro 3 oxobutanoate 0.529, 3. 8mmoles and l methylethyl 3 amino 2 butenoate 0.55g, 3.8mmoles were heated under N2 for 2 hours at 950 The cooled residue was purified by chromatography on silica eluting with ethyl acetate petroleum ether 60 80 mixtures.Pure fractions were combined, the solvent evaporated and the title compound 0.196g obtained by crystallisation from petroleum ether 60 800 mp 144 60.Example 7 3 Methyl 5 l methylethyl 4 bicyclo 2.2.2 oct 2 en 2 yl 2 fluoromethyl 1,4 dihydro 6 methyl 3r5 pyridine dicarboxylate Bicyclo 2.2.2 oct 2 en 2 carboxaldehyde 0.65g, 4.8mmoles , methyl 4 fluoro 3 oxobutanoate 0.75g,5.6mmoles and l methylethyl 3 amino 2 butenoate 0.78g, 5.4mmoles were heated at 950 for 3.5 hours.The cooled reaction mixture was purified by chromatography on silica eluting with ethyl acetate petroleum ether 60 800 mixtures to give the title compound. M 337 nmr CDC13 g5.8 s,1H and 4.5 s,lH . Example 8 3 Methyl 5 1 methylethyl 4 3 chlorobicyclo 2.2.2 oct 2 en 2 yl 2 fluoromethyl 1,4 dihydro 6 methyl 3,5 pyridinedicarboxylate 3 Chlorobicyclo 2.2.2 oct 2 en 2 carboxaldehyde 1.4g,8.2mmoles , methyl 4 fluoro 3 oxobutanoate 1.lg 8.2mmoles and .1 methylethyl 3 amino 2 butenoate 1.2g, 8.2mmoles were heated at 950 under nitrogen for 5.5 hours. The cooled reaction mixture was purified by chromatography twice on silica eluting with methylene chloride ethyl acetate and tetrahydrofuran petroleum ether 60 80 mixtures. Crystallisations from petroleum ether 60 800 gave the title compound 0.049 mp 137 80. Example 9 3 Methyl 5 l methylethyl 4 2 bromo l cyclohexenyl 2 fluoromethyl 1,4 dihydro 6 methyl 3,5 pyridine di car boxylate Prepared by the method of Example 1 and obtained as pale yellow crystals, mp 103 50.Example 10 3 Methyl 5 1 methylethyl 2 fluoromethyl 1,4 dibydro 6 methyl 4 2 trifluoromethyl 1 cyclohexenyl 3,5 pyr idinedicarboxylate Prepared by the method of Example 1 and obtained as an oil.M 419 nmr CDCl3 6.4 d,1H , 5.6 q,2H and 5.38 m,1H . Example A 2,4,6 Tris 1 methylethyl benzenesulphonyl bicyclo 2.2.2 octan 2 ylidene hydrazine Bicyclo 2.2.2 octan 2 one 2g, 16mmoles , 2,4,6 tris l methylethyl benzenesulphonyl hydrazine 4.89, 16mmoles and. conc.hydrochloric acid 0.2ml in ethanol 30ml were heated briefly at reflux and then cooled. Filtration gave the desired hydrazine 5.lg . M 404.Example B Bicyclo12.2,230ct 2 ene 2 carboxaldehyde n Butyl lithium 13.6ml of 1.6M in hexane, 22mmoles was added over 3 minutes to a stirred solution at 73 under N2 of 2,4,6 tris l methylethyl benenesulphonyl bicyclo 2.2.2 octan 2 ylidene hydrazine 2.29, 5.4mmoles in N,N,N ,N , tetramethyl 1,2 ethanediamine lOml and l,2 dimethoxyethane 50ml . After 15 minutes at the solution was warmed to 250 and then 00.Dimethylformamide 7ml was added and the mixture allowed to reach room temperature . After 30 minutes the reaction mixture was poured onto 10 sulphuric acid and, after 15 minutes, the product was extracted with ethyl acetate 3X . The organic extracts were washed with brine X 3 , saturated sodium hydrogencarbonate X 3 and brine X 3 , dried MgS04 at the solvent evaporated. Chromatography on silica eluting with ethyl acetate petroleum ether 60 800 mixtures gave the desired aldehyde 0.56g . 136 nmr CDC13 9.42 s,1H and 7.32 d,lH .Example C 3 Hydroxymethylene bicyclol2.2.2 octan 2 one A mixture of bicyclo 2.2.2 octan 2 one 2g, 16mmoles , ethyl formate 1.79g, 24mmoles , sodium metal 0.38g, 16 mmoles , ethanol lml and ether 50ml was stirred at room temperature for 16 hours. Ethanol 2ml was added and the stirring continued for 1 hour. The reaction mixture was poured into brine and extracted with ether X 2 . The aqueous layer was acidified with 10 hydrochloric acid and the product was extracted with ether X 3 . This ethereal extract was washed with brine, dried MgS04 and the solvent removed to give the title compound as an oil 1.45g . M 152 nmr CDCl3 7.1 s,1H Example 3 1 Methylethoxy methylene bicyclo 2.2.2 octan 2 one L 3 Hydroxymethylene bicyclo 2.2.2 octan 2 one 1.45g was heated at reflux with azeotropic distillation in benzene 40ml and 2 propanol 4Oml containing a catalytic quantity of 4 methylbenzenesulphonic acid.After 50ml had distilled over, the reaction mixture was cooled and then treated with solid potassium carbonate.After filtration and removal of solvent, the residue was purified by chromatography on silica eluting with ethyl acetate petroleum ether 60 80 mixtures to give the title compound as an oil 1.7g . 194 nmr CDC13 รง7.28 s,lH .Example E 3 Chlorobicyclot2.2.2 oct 2 ene 2 carboxaldehyde 3 1 Methylethoxy methylene bicyclo 2.2.2 octan 2 one 1.7g, 8.8mmoles in ether 20ml was added over 2 minutes to a stirred suspension of phosphorous pentachloride 3.64g, 17.5mmoles at 50 under nitrogen in ether 50ml . After stirring at 50 for 20 minutes and 15 for 15 minutes, brine was cautiously added.After 15 minutes, the ether layer was separated and the aqueous layer extracted with ether X 3 . The combined ethereal extracts were dried MgS04 and the solvent evaporated to give the title aldehyde 1.2g . M 170 2 nmr CDC13 9.98 s,lH .Example F l Hydroxy 2 trifluoromethyl cyclohexanecarbonitrile Trimethylsilylcyanide 3.6ml, 0.027moles was added with stirring at 180 to a solution of 2 trifluoromethyl cyclohexanone 3g, 0.018moles and zinc iodide O.lg in dichioromethane 440my . After stirring overnight, the solution was poured onto cold dilute hydrochloric acid and the product extracted with dichioromethane x3 . The combined organic extracts were washed with brine, dried MgS04 and the solvent evaporated to give 2 trifluoromethyl l trimethylsilyloxy cyclohexanecarbonitrile 4.8g as an oil. This oil was dissolved in ethanol 50ml and 10 aqueous sulphuric acid 15ml and stirred for 1.5 hours.The ethanol was removed under reduced pressure and the residue treated with brine and ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate x3 . The combined organic extracts were washed with brine, dried MgS04 and the solvent evaporated to give the title compound 3.29 as a mixture of epimers.nmr CDC13 93.3 and 2.85 2xbrs, 1H and 2.5 m,lH Example G 2 Trifluoromethyl 1 cyclohexenecarbonitrile and 6 trifluoromethyl 1 cyclohexenecarbonitrile 1 Hydroxy 2 trifuoromethyl cyclohexane carbonitrile 16.3g, 0.084moles , phosphorous oxychioride 152ml, 1.7moles , pyridine 134ml, 1.7moles and benzene 600ml were heated at reflux for 6 hours. After cooling to room temperature the reaction mixture was cautiously added to ice.After 45 minutes the product was extracted with eher ethyl acetate x4 . The combined organic extracts were washed with brine x3 , dried MgSO4 and the solvent evaporated. The two isomeric nitriles were separated by chromatography on silica eluting with ethyl acetate petroleum ether 6080O mixtures. The 2 trifluoromethyl nitrile 3.3g was eluted first M l75 nmr CDCl3 2.45 and 2.35 2xm, 2x2H and 1.72 m, 4H followed by the 6 trifluoromethyl nitrile 5.2g M l75 nmr CDCl3 7.0 m,lH . Example H 2 Trifluoromethyl 1 cyclohexenecarboxaldehyde Diisobutylaluminium hydride 3.75ml of 1.4M in toluene, 5.3mmoles was added to a stirred solution of 2 trifluoromethyl 1 cyclohexenecarboxaldehyde 0.45g, 2.6mmoles in benzene 25ml under nitrogen at 150.After 2.5 hours, the solution was cooled in ice and 10 aqueous sulphuric acid was added. The product was extracted with ethyl acetate tx3 and the coinbined extracts were washed with brine, dried MgSO4 and the solvent evaporated to leave the desired aldehyde 0.25g M 178 nmr CDCl3 10.1 q,lH .